| Document |
Document Title |
|
WO/2022/263829A1 |
The invention relates to compounds or salts of Formula (I-a), Formula (I-b), Formula (I-c), Formula (I-d), Formula (II) and pharmaceutical compositions containing these compounds. The compounds may be inducers of α1-antitrypsin (A1AT), ...
|
|
WO/2022/264072A1 |
The present invention relates to polymorphic forms of Tafamidis of Formula I and process for their preparation and pharmaceutical composition comprising it.
|
|
WO/2022/257833A1 |
The present application relates to an intermediate of a phenylpropyl pyridine derivative and a preparation method for the intermediate. The intermediate is a compound as represented by formula (I) or a pharmaceutically acceptable salt th...
|
|
WO/2022/255764A1 |
The present invention relates to a novel oxazole derivative, a preparation method therefor, and a pharmaceutical composition containing same as an active ingredient for preventing or treating an allergic disease such as asthma or atopy. ...
|
|
WO/2022/251567A1 |
Methods of making benzoxazepin oxazolidinone compounds as well as synthetic intermediates are described, including compound (10-2) and compound 18.
|
|
WO/2022/251818A1 |
Pro-benefit-agent compounds having heterocyclic moieties that include a benefit agent fragment derived from benefit agents, such as perfume raw materials, that include an aldehyde moiety or a ketone moiety. The pro-benefit-agent compound...
|
|
WO/2022/243097A1 |
A process to produce N-vinyl compounds by homogeneous catalysis, wherein acetylene is re-acted with a compound having at least one nitrogen bearing a substitutable hydrogen residue in a liquid phase in the presence of at least one phosph...
|
|
WO/2022/239020A1 |
Aspects of the present application relates to crystalline Form TLP of Tafamidis. The present application provides a process for the preparation of crystalline Form TLP of Tafamidis, comprising the step of crystallizing from a mixture com...
|
|
WO/2022/234069A1 |
This invention relates to 2-aminooxazole derivatives of general formula (I) or a pharmaceutically acceptable salt or solvate thereof wherein Y and Z are two different heteroatoms selected from N and O; X is selected from N and CR12; and ...
|
|
WO/2022/236118A1 |
Provided herein are fatty acid amide (FAAH) cleavable prodrugs of compounds that modulate a target in the brain including sphingosine- 1 -phosphate receptor (S1P1), lysophosphatidic acid receptor 1 (LPA1), G-protein coupled receptor 120 ...
|
|
WO/2022/229026A1 |
A crystalline form of 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid and a method for its preparation are described. The crystalline form is further suitable as intermediate compound to prepare Form 1, Form 4 and Form M with im...
|
|
WO/2022/218399A1 |
Disclosed are a central chirality induced spiro chiral tetradentate cyclometalated platinum (II) and palladium (II) complex-based circularly polarized luminescence material and an application thereof. Spiro chiral metal complex molecules...
|
|
WO/2022/218733A1 |
The present invention provides a process for producing a substituted enamine compound of formula (I), and a process for producing oxazole compounds from the compound of formula (I). According to the processes of the present invention, it...
|
|
WO/2022/219246A1 |
The present invention relates to a compound of formula (I) wherein A, Z, L, R1, R2, R3, R4, R5 and R33 are as defined in claim 1, or a pharmaceutically acceptable salt thereof. The compounds of formula (I) possess utility as inhibitors o...
|
|
WO/2022/218734A1 |
The present invention provides a substituted enamine compound of formula (I), and a process for producing oxazole compounds from the compound of formula (I). According to the processes of the present invention, it can produce substituted...
|
|
WO/2022/189856A9 |
This invention provides compounds, for example, of Formulae (A)-(H) and (J)-(AA) and pharmaceutically acceptable salts, solvates, esters, amides, and prodrugs thereof. The invention further provides pharmaceutical compositions comprising...
|
|
WO/2022/211574A1 |
The present invention relates to a composition for preventing or treating chronic kidney diseases (CKDs), comprising a compound that induces the expression of anti-aging gene klotho. The composition represented by chemical formula 1, acc...
|
|
WO/2022/203246A1 |
The present specification relates to a compound represented by chemical formula 1 and an organic light-emitting device comprising same.
|
|
WO/2022/204080A1 |
This disclosure relates to the field of molecules having pesticidal utility against pests in Phyla Arthropoda, Mollusca, and Nematoda, processes to produce such molecules, intermediates used in such processes, pesticidal compositions con...
|
|
WO/2022/200247A1 |
The present invention is related to the synthesis of 4-hydroxymethyl-2-oxazolidinone (serinol carbamate, SC), which can be subsequently hydrolyzed to 2-amino-1,3-propanediol (serinol), by reacting glycerol and urea: (I) In general, glyce...
|
|
WO/2022/191338A1 |
An object of the present invention is to provide a combination medicament useful for treatment of Parkinson's disease. The present invention provides a prophylactic or therapeutic agent for Parkinson's disease, the agent containing a com...
|
|
WO/2022/182153A1 |
The present invention provides a novel compound and an organic light emitting device using same.
|
|
WO/2022/178228A1 |
The invention provides arylthioether acetamide and related compounds, pharmaceutical compositions, and their use in the treatment of medical conditions, such as bacterial infections, and in inhibiting LpxA activity.
|
|
WO/2022/172744A1 |
The purpose of the present invention is to provide an efficient method of producing a carbonyl halide for a halogenated methane used. A method for producing a carbonyl halide according to the present invention is characterized by compris...
|
|
WO/2022/172786A1 |
Provided is a compound, represented by formula (1) below, useful for treating cancer or the like. In the formula, R1 and R3-R8 each independently indicate a hydrogen atom or an alkyl group. R2 indicates a hydrogen atom or a group represe...
|
|
WO/2022/172994A1 |
The present invention provides a method for producing an oligonucleotide having a phosphate ester bond by oxidizing an oligonucleotide precursor having a phosphite ester bond or a phosphonic acid ester bond via an oxidizing agent, wherei...
|
|
WO/2022/172745A1 |
The purpose of the present invention is to provide a method for producing a halogenated carbonyl efficiently in regard to the used halogenated hydrocarbons. The method for producing a halogenated carbonyl according to the present inventi...
|
|
WO/2022/168755A1 |
The present invention provides a nonaqueous electrolyte solution comprising: (I) at least one compound selected from the group consisting of compounds represented by general formula (1) in the description (for example, compounds represen...
|
|
WO/2022/166767A1 |
Disclosed are a pharmaceutically acceptable salt of an HA inhibitor (1S, 2S)-2-fluoro-N-(2-(2-(4-((R)-(5-methyl-2H-tetrazol-2-yl) (phenyl) methyl) piperidine-1-formyl) pyridine-4-yl) benzo[d]oxazol-5-yl) cyclopropyl-1-carboxamide, or a h...
|
|
WO/2022/163843A1 |
Provided are a compound having high PIM2 inhibitory activity, and a PIM2 inhibitor and a pharmaceutical composition that contain the compound. This PIM2 inhibitor contains a compound represented by formula (1) (in the formula, A is a ben...
|
|
WO/2022/165198A1 |
A liner in a label-liner combination is provided with a die cut portion made in the liner. The die cut portion is aligned with at least one edge in a label and a front side of the liner is attached to a backside of the label. The die cut...
|
|
WO/2022/158758A1 |
Provided is an organic compound which contributes to substantial improvements in the luminous efficiency and viewing angle of an organic electroluminescent device. An organic electroluminescent device according to the present invention c...
|
|
WO/2022/156737A1 |
Disclosed are a crystal form of a compound (1S, 2S)-2-fluoro-N-(2-(2-(4-((R)-(5-methyl-2H-tetrazol-2-yl) (phenyl) methyl) piperidine-1-formyl) pyridin-4-yl) benzo [d] oxazol-5-yl) cyclopropyl-1-carboxamide having a structure of formula (...
|
|
WO/2022/159445A1 |
The present disclosure is generally directed to activators of lipoprotein lipase useful in the treatment of diseases and disorders modulated by said enzyme and having the Formula (I), or a pharmaceutically acceptable salt, isomer, solvat...
|
|
WO/2022/146086A1 |
The present invention relates to: a compound that is sensitive to γ-hydroxybutyric acid (GHB)-based compounds, and thus changes color; and an application thereof, and since the GHB-based compound-sensitive chromogenic compound of the pr...
|
|
WO/2022/136366A1 |
The present invention relates to a novel method for producing NCA compounds. The invention also relates to a novel use of a peptide coupling agent. The method according to the invention enables NCA compounds to be obtained from α-amino ...
|
|
WO/2022/140520A1 |
Methods are provided for modulating MRGPRX2 generally, or for treating a MRGPRX2 dependent condition more specifically, by contacting the MRGPRX2 or administering to a subject in need thereof, respectively, an effective amount of a compo...
|
|
WO/2022/138944A1 |
The present disclosure provides a pharmaceutical composition for treating and/or preventing SWI/SNF complex-dysfunction cancer. More specifically, according to the present disclosure, a compound represented by formulae (1) to (23) (the f...
|
|
WO/2022/132696A1 |
The present invention is directed to urea compounds which are agonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psy...
|
|
WO/2022/127704A1 |
Disclosed are a method for preparing a carboxyl cyclic acid anhydride and a prepared product thereof. A method for preparing a compound of formula (II), comprising the steps of reacting a compound of formula (I) with a cyclization reagen...
|
|
WO/2022/129047A2 |
The present invention is directed to novel modulators of the NMDA receptor. Separate aspects of the inventions are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat neurological disorder...
|
|
WO/2022/129909A1 |
The present invention relates to a group of novel compounds, methods for their manufacture and the use of these compounds as research tools and as pharmaceuticals. The novel compounds are analogues of cannabidiol (CBD). CBD is a non-psyc...
|
|
WO/2022/122773A1 |
The present invention relates to 4-(2-Fluoro-4-methoxy-5-3-(((l- methylcyclobutyl)methyl)carbamoyl)bicyclo[2.2.1]heptan-2-yl)
carbamoyl)phenoxy)-l-methylcyclohexane-l-carboxylic acid derivatives and similar compounds of formula (I) as R...
|
|
WO/2022/121228A1 |
Disclosed are a preparation and an application of an oxazole and thiazole histone deacetylase (HDAC) inhibitor. The chemical structure of the inhibitor is represented by formula (I). The inhibitor has relatively strong inhibitory activit...
|
|
WO/2022/112140A1 |
The present invention provides novel compounds having the general formula (I) wherein Al to A4, Li, L2, R1 and R2 are as described herein, compositions including the compounds and methods of using the compounds for the treatment of HBV i...
|
|
WO/2022/111605A1 |
The present disclosure relates to an aryl or heteroaryl substituted 5-membered aromatic heterocyclic compound and the use thereof. In particular, provided is a compound as shown in formula I or a pharmaceutically acceptable salt thereof,...
|
|
WO/2022/109362A1 |
This disclosure relates to aryl amidines of Formula (I) and their use as fungicides.
|
|
WO/2022/107166A1 |
The present invention relates to novel crystalline Forms of Tafamidis and process to prepare thereof. The present invention also relates to process of Tafamidis N-methyl-D-glucamine.
|
|
WO/2022/106589A1 |
The present invention provides novel compounds having the general formula (I) wherein R1 to R6 are as described herein, compositions including the compounds and methods of using the compounds.
|
|
WO/2022/100099A1 |
An organic compound, a mixture, a composition and an organic electroluminescence device. The organic compound has a high extinction coefficient in the ultraviolet region; has a high refractive index in the visible light region; can be us...
|
